Neuroendocrine regulation and obesity

A knowledge gap exists in understanding how neuroendocrine systems contribute to metabolic syndrome. Prior research has shown that insulin resistance and cortisol dominance are linked to metabolic dysregulation. However, the exact mechanisms connecting these hormonal imbalances to obesity remain unclear. Established knowledge includes the role of insulin in glucose regulation and cortisol in stress responses. No prior work had resolved how these hormones interact in obesity. This uncertainty drives the need for a deeper analysis of endocrine interactions. The syndrome of upper body obesity, diabetes, and hypertension is poorly understood at the hormonal level. This paper aims to clarify the hormonal pathways involved in the syndrome.

The aim is to explore how neuroendocrine regulation contributes to the syndrome of upper body obesity and related metabolic issues. The specific problem is the unclear role of insulin and cortisol in energy balance. The motivation comes from the need to better understand hormonal interactions in obesity. The authors propose that imbalances in insulin and cortisol may explain the syndrome's features. This paper seeks to synthesize evidence on how these hormones affect metabolism. The focus is on the antagonism and synergism between insulin and cortisol. The goal is to identify how these interactions lead to obesity and metabolic dysfunction. The study also examines the role of serotonin in regulating food intake and hormonal balance.

The study uses a review approach to synthesize existing literature on neuroendocrine regulation. The authors analyze the roles of insulin, cortisol, and serotonin in metabolic control. They examine how insulin insensitivity and cortisol dominance affect energy balance. The review includes evidence on the antagonism between insulin and cortisol in glucose regulation. The synergism between these hormones in energy storage is also explored. The role of corticotropin-releasing factor in energy expenditure is considered. The authors assess the impact of D-fenfluramine on food intake and hormonal balance. The review focuses on how these factors contribute to obesity and metabolic syndrome.

The strongest finding is that insulin insensitivity and cortisol dominance are linked to metabolic syndrome. The antagonism between insulin and cortisol contributes to hyperglycaemia and dyslipidemia. The synergism between these hormones increases energy storage in fat tissue. Decreased corticotropin-releasing factor activity reduces energy expenditure. D-fenfluramine appears to reduce food intake through serotoninergic pathways. It may also normalize hormonal balance via the hypothalamic-pituitary-adrenal axis. The evidence suggests that neuroendocrine imbalances drive obesity and related conditions. These findings highlight the role of hormonal interactions in metabolic dysregulation.

The authors propose that neuroendocrine imbalances are central to the syndrome of upper body obesity. They suggest that insulin insensitivity and cortisol dominance are key factors. The antagonism between insulin and cortisol may explain hyperglycaemia and dyslipidemia. The synergism between these hormones likely contributes to fat accumulation. Decreased corticotropin-releasing factor activity may reduce energy expenditure. D-fenfluramine's effects on serotonin may normalize hormonal balance. The authors suggest that these findings could inform obesity treatment strategies. They emphasize the need for further research on neuroendocrine regulation in metabolic syndrome.